Early Breast Cancer Clinical Trials

68 clinical trials for Early Breast Cancer across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests — RECRUITING · PHASE3
• A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) — RECRUITING · PHASE3
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer — RECRUITING · PHASE3
• Refusal of Sentinel Lymph Node Biopsy in Patients With Luminal A Subtype Early Breast Cancer — RECRUITING · NA
• Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer — RECRUITING
• Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients — RECRUITING · NA
• Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers — RECRUITING · NA
• MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC — RECRUITING · PHASE2
• Mediterranean Diet and Inequality in Early Breast Cancer — RECRUITING · PHASE2
• A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study) — RECRUITING · NA
• Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer — RECRUITING
• Impact of "Targeted" Nutritional Apport and Exercise on the Modulation of Metabolic and Immune-related Gene Expression Signatures in Early Breast Cancer (eBC) Patients Candidate to Neoadjuvant Therapy (NAT) — RECRUITING · NA
• Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer — RECRUITING · PHASE2
• The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer — RECRUITING · NA
• Not Available — COMPLETED · PHASE2
• Randomized Phase II Study of Dose-Dense Fluorouracil Plus Epirubicin75 Plus Cyclophosphamide (FEC75) and Fluorouracil Plus Epirubicin90 Plus Cyclophosphamide (FEC90) as Adjuvant Therapy for Early Breast Cancer — COMPLETED · PHASE2
• Genomics guided targeted post-neoadjuvant therapy in patients with early breast cancer – a multicenter, open-label, umbrella phase-II study (COGNITION-GUIDE) — TERMINATED · PHASE2
• PREDIX Luminal B - Neoadjuvant response-guided treatment of estrogen receptor positive tumors with high proliferation or slow proliferation with metastatic nodes. Part of a platform of translational phase II trials based on molecular subtypes. — TERMINATED · PHASE2
• neoAGORA: Exploring Clinical Utility of Serial Liquid Biopsy (ctDNA) in Patients With Early-Stage Breast Cancer — NOT_YET_RECRUITING
• Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial — NOT_YET_RECRUITING · PHASE2
• A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) — ACTIVE_NOT_RECRUITING · PHASE3
• Impact of EXercise on quality of life of early breast cancer patients on treatment with adjuvant Aromatase Inhibitors with or without CDK4/6 inhibitors. "The EX-AI study" — TERMINATED · PHASE4
• Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• The Prognostic Role of TILs and CD8+ T Cells in Operable Breast Cancer — COMPLETED
• Independent, External, Blinded Retrospective Validation of an AI-based Prognostic Assay in ER-Positive/HER2-Negative Early Breast Cancer — ACTIVE_NOT_RECRUITING
• A Real-World Study on the Impact of Different Adjuvant Treatment Regimens on Prognosis in Non-pCR Patients With HER2-Positive Breast Cancer After Neoadjuvant Therapy — NOT_YET_RECRUITING
• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients — ACTIVE_NOT_RECRUITING · PHASE2
• Evaluation of Adherence to Cell Cycle Inhibitors Used as Adjuvant Therapy in Patients With Localized Breast Cancer at High Risk of Recurrence. — NOT_YET_RECRUITING
• De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Correlation Between Tumor-infiltrating Lymphocytes and Response to Systemic Therapy in Breast Cancer — COMPLETED
• A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer — COMPLETED · PHASE3
• Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer — ACTIVE_NOT_RECRUITING · NA
• An Observational Real-world Study to Evaluate the Impact of Dermatological Toxicities on the Quality of Life in Patients With Early Breast Cancer Treated With Adjuvant Endocrine Therapy - BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological Adverse Events) — COMPLETED
• This Clinical Trial is a Retrospective, Multicenter Cohort Study Evaluating the Real-world Characteristics and Risk of Disease Recurrence in Hormone Receptor-positive, HER2-negative Early Breast Cancer. — NOT_YET_RECRUITING
• SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study — NOT_YET_RECRUITING · PHASE2
• Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer. — WITHDRAWN · PHASE3
• SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response — NOT_YET_RECRUITING · PHASE2
• Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients — NOT_YET_RECRUITING · PHASE2
• Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer Patients — ACTIVE_NOT_RECRUITING · NA
• Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy — NOT_YET_RECRUITING
• Aromatherapy in the Treatment of Early Breast Cancer — NOT_YET_RECRUITING · PHASE2
• A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer — COMPLETED · PHASE3
• QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer — NOT_YET_RECRUITING · PHASE2
• QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer — NOT_YET_RECRUITING · PHASE2
• Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab — NOT_YET_RECRUITING · PHASE2
• A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity — COMPLETED · PHASE2
• Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status — COMPLETED
• Activity Program During Aromatase Inhibitor Therapy — COMPLETED · NA
• Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients — ACTIVE_NOT_RECRUITING

Refine this search